
News|Articles|April 1, 2002
Reference pricing does not compromise outcomes of ACE inhibitor therapy
Concerns about possible unintended consequences of reference pricing-atleast when applied to ACE inhibitors-appear to be unfounded, according toa new analysis of Canadian data.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilars in 2025: A year of firsts
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Music and painting dual art therapy improves cognitive and social functions of hospitalized schizophrenia patients, study suggests
4
Low uptake of shingles vaccine despite strong value proposition for older adults
5






















































